Emerging treatment options for prostate cancer: A review of targeted therapies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
A 67-year-old retired schoolteacher from Jutland arrived at our clinic in the spring of 2020 with metastatic castration-resistant prostate cancer that had progressed through two lines of androgen deprivation therapy. Within eighteen months, a targeted treatment based on his tumor's BRCA2 mutation status had reduced his PSA by 78% and allowed him to return to tending his garden-a result that would have been unthinkable a decade earlier. His experience reflects a broader transformation in how clinicians approach advanced prostate cancer, where targeted molecular therapies have begun to supplement and in some cases supplant the traditional hormone-chemotherapy sequence that dominated treatment algorithms for decades. This research presents a review of targeted therapy outcomes in 109 patients with advanced prostate cancer treated at two Danish academic urology centers between March 2020 and December 2021. Patients received one or more targeted agents including androgen receptor pathway inhibitors (enzalutamide, abiraterone), poly-ADP ribose polymerase inhibitors (olaparib, rucaparib) for those harboring homologous recombination repair gene mutations, radioligand therapy with lutetium-177 PSMA, PI3K/AKT pathway inhibitors, and immune checkpoint inhibitors for microsatellite instability-high tumors. PSA response rates, defined as a decline of 50% or greater from baseline confirmed at four weeks, ranged from 31.4% for pembrolizumab in MSI-high disease to 58.3% for enzalutamide. Combination regimens pairing an androgen receptor agent with a PARP inhibitor achieved the highest overall PSA response at 62.5%. Median progression-free survival varied substantially across treatment categories, with androgen receptor-targeted agents achieving 16.5 months, combination regimens 13.2 months, PARP inhibitors 10.8 months in BRCA-mutated patients, and radioligand therapy 8.7 months. Adverse event profiles differed meaningfully between therapeutic classes, with PARP inhibitors producing the highest rates of anemia (46.2%) and androgen receptor agents the highest rates of hypertension (31.7%), while radioligand therapy demonstrated the most balanced toxicity profile. Box-plot analysis revealed wide variation in individual patient outcomes within each treatment category, with progression-free survival ranging sevenfold among PARP inhibitor recipients, highlighting the current inability to predict at baseline which patients will derive the greatest benefit from specific targeted agents. Molecular profiling data supported the clinical utility of distinguishing between specific HRR gene alterations, with BRCA1/2-mutated patients achieving substantially longer progression-free survival than those with non-BRCA HRR mutations on PARP inhibitor therapy. This review underscores the rapidly expanding therapeutic landscape for advanced prostate cancer and emphasizes the growing importance of molecular profiling in guiding individualized treatment selection decisions.
Fields of Study & Subjects
Prostate Cancer Treatment and Research
Prostate Cancer Diagnosis and Treatment
PARP inhibition in cancer therapy
Publication details
- Journal / source
- International Journal of Urology Sciences
- Volume
- 8
- Issue
- 1
- Pages
- 31–37
- Publication date
- 1 January 2026
- Language
- EN